Tradestie Institutional Equity Comparison Engine · Market Close Oct 29, 2026

SBLX vs LNAI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SBLX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–0 Matrix Metrics)

SBLX Overall Winner 6-Pillar Tally: SBLX 3 – 1 LNAI (2 Tie) Matrix Metrics: SBLX 5 – 0 LNAI

As of Oct 29, 2026, StableX Technologies, Inc. (SBLX) is the stronger overall head-to-head candidate over Lunai Bioworks Inc. (LNAI) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). SBLX carries a Unified Composite Score of 65.5/100 (BUY) at $3.10 (N/M Forward P/E, 0.0% operating margin), whereas LNAI carries 44.1/100 (HOLD) at $0.16 (N/M Forward P/E, -6888.6% operating margin).

  • Technical & Structure Timing Caution: SBLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 67.4); meanwhile LNAI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SBLX vs LNAI
SBLX NASDAQ Head-to-Head Winner
StableX Technologies, Inc. Common Stock
Communications Services, Nec
$3.10
+23.51% 1D
Market Cap $3.7M
TTM Revenue $5,426
Forward P/E N/M
Beta / 30D Vol 3.68β · 114% Vol
Unified Composite Score
65.5 / 100 BUY
Tech 60.0 Fund 58.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 67
RSI-14: 67.4 · SMA20: $2.38 · SMA50: $2.42
LNAI NASDAQ
Lunai Bioworks Inc. Common Stock
Pharmaceutical Preparations
$0.16
-30.2% 1D
Market Cap $1.2M
TTM Revenue $51,992
Forward P/E N/M
Beta / 30D Vol 3.92β · 186% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 45.0 Fund 43.0 Flow 43.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.8%), weak momentum, RSI 13
RSI-14: 13.3 · SMA20: $0.74 · SMA50: $1.61

6-Pillar Scorecard Institutional Category Breakdown (SBLX 3 – 1 LNAI)

Columns: Metric · SBLX · LNAI
1. Valuation Multiples SBLX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 113.4x N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5,426 $51,992
Market Cap $3.7M $1.2M
3. Profitability & Quality SBLX
Gross Margin N/A 100.0%
Operating Margin 0.0% -6888.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -191.9% -325.5%
4. Balance Sheet & Cash Flow LNAI
Cash Generation (TTM) -$7.3M -$7.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.0M Net Cash $1.7M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SBLX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Auto Manufacturers Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SBLX (5) vs LNAI (0)
Institutional Metric SBLX LNAI Criterion Row Edge
Market Capitalization
Scale
$3.7M $1.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -6888.6% Higher Margin SBLX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-191.9% -325.5% Higher ROE SBLX
52-Week Range Position
Momentum
27% ($0–$11) 0% ($0–$5) Stronger Trend SBLX
Beta / 30D Volatility
Risk Regime
3.68β · 114% Vol 3.92β · 186% Vol Lower Realized Risk SBLX
Unified Institutional Score
Composite Signal
65.5 / 100 (BUY) 44.1 / 100 (HOLD) Higher Composite SBLX
Trailing 12M Revenue (USD)
Operating Scale
$5,426 $51,992 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 113.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.3M ($3.0M Net Cash) -$7.8M EBITDA ($1.7M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBLX +87.08 pp
SBLX: +69.4% · LNAI: -17.68%
3M Horizon SBLX +67.89 pp
SBLX: +8.39% · LNAI: -59.5%
6M Horizon SBLX +34.72 pp
SBLX: -32.61% · LNAI: -67.33%
1Y Horizon SBLX +34.72 pp
SBLX: -32.61% · LNAI: -67.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SBLX vs LNAI. Trailing 12-month operating profitability (SBLX 0.0% vs LNAI -6888.6%) and valuation multiples (SBLX N/M vs LNAI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SBLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5,426
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-191.9% · N/M
LNAI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$51,992
Gross Margin100.0%
Op. Margin-6888.6%
ROE / Fwd P/E-325.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SBLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SBLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LNAI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LNAI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SBLX Moat Profile Cyclical / Execution-Driven Positioning
Auto Manufacturers Operator
Competes within the Auto Manufacturers value chain with $3.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LNAI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2M market capitalization and -6888.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SBLX vs LNAI Key Questions & Quantitative Answers

As of Oct 29, 2026, StableX Technologies, Inc. (SBLX) is the stronger overall head-to-head candidate over Lunai Bioworks Inc. (LNAI) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). SBLX carries a Unified Composite Score of 65.5/100 (BUY) at $3.10 (N/M Forward P/E, 0.0% operating margin), whereas LNAI carries 44.1/100 (HOLD) at $0.16 (N/M Forward P/E, -6888.6% operating margin). Technical & Structure Timing Caution: SBLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 67.4); meanwhile LNAI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SBLX and LNAI split Growth & Scale metrics: SBLX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $5,426 TTM revenue (N/A gross margin, 0.0% operating margin), compared with LNAI at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $51,992 TTM revenue (100.0% gross margin, -6888.6% operating margin). On trailing 12-month operating scale, SBLX generates $5,426 in USD-normalized revenue versus $51,992 for LNAI. In operating R&D and SG&A reinvestment, SBLX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LNAI.

SBLX screens cheaper on headline valuation multiples. SBLX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 113.4x EV/Revenue (unreported FCF margin), whereas LNAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SBLX (-191.9% ROE) versus LNAI (-325.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SBLX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.68β · 114% Vol realized risk). By comparison, LNAI carries 0.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.92β · 186% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Oct 29, 2026. For educational research only; not investment advice.